<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322892/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322892</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Novel hydrophobic tag degraders overcome endocrine-resistant breast cancer by recruiting HSP27-mediated E3 ligase complex for ERα proteasomal degradation</name><description>Hydrophobic tag (HyT)-mediated protein degradation has emerged as a pivotal tool for targeted protein degradation (TPD), yet its underlying degradation mechanism remains incompletely elucidated. Herein, we designed structurally optimized HyT-based degraders by covalently conjugating hydrophobic amino acid tags to ERα-targeting ligands via alkane linkers of varying lengths, identifying the lead compound VI-10h. VI-10h exhibited potent antiproliferative activity and efficient ERα degradation in endocrine-resistant breast cancer cells (LCC2, MCF-7D538G, MCF-7Y537S, and MCF-7EGFR) and superior antitumor activity compared to the clinical drug fulvestrant (Ful) in MCF-7 and tamoxifen-resistant LCC2 xenograft models. To elucidate the HyT-mediated degradation mechanism, we synthesized biotin-conjugated HyTs (biotin-Lys and biotin-Trp) and performed pull-down assays combined with mass spectrometry. Our results unveiled that VI-10h selectively recruits HSP27 as a novel atypical E3 ligase adaptor protein, forms an ERα-HSP27-RING1 ternary complex to promote ERα degradation, disrupts estrogen-dependent oncogenic networks, and circumvents the drug resistance associated with conventional CRBN- or VHL-dependent E3 ligase-recruiting degraders. This study validates HyT technology’s degradation mechanism and feasibility in reversing resistance to conventional E3 ligases and overcoming endocrine-resistant breast cancer, establishing a molecular design strategy for next-generation targeted degraders that reverse endocrine resistance.</description><dates><publication>2026/07/29</publication></dates><accession>GSE322892</accession><cross_references><GSM>GSM9560576</GSM><GSM>GSM9560577</GSM><GSM>GSM9560578</GSM><GSM>GSM9560582</GSM><GSM>GSM9560583</GSM><GSM>GSM9560584</GSM><GSM>GSM9560580</GSM><GSM>GSM9560581</GSM><GSM>GSM9560579</GSM><GPL>24676</GPL><GSE>322892</GSE><taxon>Homo sapiens</taxon><PMID>[42189698]</PMID></cross_references></HashMap>